Immunosuppressive CD14⁺HLA-DR^lo/neg monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes.

ABSTRACT: Immunological strategies to treat pancreatic cancer offer new therapeutic approaches to improve patient outcomes. Understanding alterations in the immune systems of pancreatic cancer patients will likely lead to advances in immunotherapy for the disease. We profiled peripheral blood leukocytes from pancreatic cancer patients (n = 22) and age-matched controls (n = 20) using flow cytometry. Immune profiling of pancreatic cancer patients identified phenotypic changes in various immune cell populations, including a population of immunosuppressive monocytes (CD14⁺HLA-DR^lo/neg), which were shown to be increased in these patients. There was a correlation between the levels of CD14⁺ monocytes and the levels of CD14⁺HLA-DR^lo/neg m

SUBMITTER: Javeed N 

PROVIDER: S-EPMC5283619 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature